This website is intended for US healthcare professionals only

US Medical Affairs

Congress Presentations

Stay informed about the latest scientific and medical research from Axsome.

American Headache Society (AHS) 2025

Minneapolis, MN | June 19 - 22, 2025

Symbravo® | Migraine

Plenary Presentation: Efficacy and Safety of Symbravo® (MoSEICTM Meloxicam and Rizatriptan) in Participants With Migraine Experiencing an Inadequate Response to Oral CGRP Inhibitors: Topline Results From the EMERGE Trial

View / Download

Symbravo® | Migraine

Long-Term Effects of Symbravo® (MoSEICTM Meloxicam and Rizatriptan) on Headache Burden and Quality of Life: Results of the MOVEMENT Trial

View / Download

Symbravo® | Migraine

Efficacy of Symbravo® (MoSEICTM Meloxicam and Rizatriptan) by Baseline Migraine-Associated Disability: Post-hoc Analysis of the INTERCEPT Trial

View / Download
footer graphic

This site contains scientific information about investigational compounds and/or information about products and/or uses that have not been approved by the US Food and Drug Administration. The safety and efficacy of investigational products and/or investigational uses of approved products has not been established and such investigational products/uses have not and may not be approved for marketing by any health authority.

AXSOME, AUVELITY, SUNOSI, SYMBRAVO and their logos are trademarks or registered trademarks of Axsome Therapeutics, Inc. or its affiliates. Other trademarks are property of their respective owners.

© 2025 Axsome Therapeutics, Inc. All rights reserved. One World Trade Center, New York, NY 10007